Table 2 Relationship between p62 expression and clinicopathological variables
From: High expression of p62/SQSTM1 predicts shorter survival for patients with pancreatic cancer
Variable | p62 low | p62 high | pa |
|---|---|---|---|
Patients, n (%) | 19 (57.6) | 14 (42.4) | 0.255b |
Median age, years (range) | 62 (50–76) | 62.5 (52–80) | 0.733b |
Age, n (%) | |||
<65 years | 12 (63.2) | 8 (57.1) | |
≥65 years | 7 (36.8) | 6 (42.9) | 0.727 |
Sex, n (%) | |||
Female | 7 (36.8) | 8 (57.1) | |
Male | 12 (63.2) | 6 (42.9) | 0.247 |
Tumor location, n (%) | |||
Head | 17 (89.5) | 13 (92.9) | |
Others | 2 (10.5) | 1 (7.1) | 0.738 |
Tumor stage, n (%) | |||
pT1 | 2 (10.5) | 1 (7.1) | |
pT2 | 8 (42.1) | 5 (35.7) | |
pT3 | 9 (47.4) | 5 (35.7) | |
pT4 | 0 (0) | 3 (21.4) | 0.211 |
Differentiation, n (%) | |||
Low | 7 (36.8) | 3 (21.4) | |
Medium | 7 (36.8) | 7 (50.0) | |
High | 3 (15.8) | 2 (14.3) | 0.617 |
Data missing | 2 (10.5) | 2 (14.3) | |
Lymph node metastasis, n (%) | |||
N0 | 10 (52.6) | 5 (35.7) | |
N1 | 9 (47.4) | 9 (64.3) | 0.335 |
Adjuvant chemotherapy, n (%) | |||
No | 14 (73.7) | 12 (85.7) | |
Yes | 5 (26.3) | 2 (14.3) | 0.403 |
LC3, n (%) | |||
Low | 13 (68.4) | 5 (35.7) | |
High | 6 (31.6) | 9 (64.3) | 0.062 |
NRF2, n (%) | |||
Low | 9 (47.4) | 5 (35.7) | |
High | 10 (52.6) | 9 (64.3) | 0.503 |